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heart catheterization will be needed to accurately
measure both left and right heart pressures.
Another interesting but disturbing observation is
the very poor mortality rate observed in the sub-
group of individuals with concomitant left ventricu-
lar dysfunction. Possibly, the preservation of cardiac
output is as important in patients with IPF-associ-
ated PH as in those with idiopathic pulmonary
arterial hypertension.
So, what will it take to change the fatalism with
which many pulmonary physicians approach IPF?
Since corticosteroid and antifibrotic therapies have
not yet proven to be beneficial in randomized trials,
might there be other options to improve IPF out-
comes? Should we begin ordering serial echocardi-
ography or measurements of brain natriuretic pep-
tide levels5 to define the frequency of PH with rest
and exercise as a target for therapy? The answer will
be realized after the next round of clinical trials
directed at IPF-induced PH, targeting functional
outcomes.
Because IPF and most interstitial lung diseases are
heterogeneous, some healthy blood vessels likely
remain. These blood vessels, which are localized in
areas of preserved lung parenchyma, might be ame-
nable to vasodilator therapy, particularly if medial
hypertrophy in response to pressure overload has
developed. One challenge will be to match ventila-
tion and perfusion to avoid worsened exercise hypox-
emia.
There are other diseases in which so called fixed
pulmonary artery hypertension has proven amena-
ble to drug therapy. The response of thromboem-
bolic PH6,7 and sarcoidosis8 to epoprostenol therapy
serves as an example of how those blood vessels
remaining in the lung may vasodilate and marginally
improve cardiac output, pulmonary vascular resis-
tance, and symptoms. Future trials in IPF patients
will use the data of Nadrous et al to risk stratifying
the patients and justify medication trials. These trials
seem justified in the investigation of this devastating
pulmonary disease.
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Airflow Limitation as a
Screening Tool
Too Relevant To Ignore, Too
Conspicuous To Apply?
C linical logic tells that loss of pulmonary functionheralds decline in (respiratory) health status, and
the study of Xie et al1 in this issue of CHEST (see
page 2448) may help further explore this logic.
Pulmonary function decline gains importance when
its impact on the general population is taken into
account. Our study in family medicine, the Detec-
tion, Intervention and Monitoring of COPD and
Asthma (DIMCA) program, for example, detected in
1991 a persistently reduced lung function or in-
creased bronchial hyperresponsiveness in 7.7% of
the general population, whereas another 12.5%
showed a rapid decline in lung function ( 80
mL/yr) in combination with signs of bronchial hyper-
responsiveness.2 A further 19.4% showed mild ob-
jective signs of COPD or asthma. However, research
failed to directly confirm intuition; in analyzing
airflow limitation in conjunction to other patient
characteristics, a poor correlation was found between
FEV1 and respiratory signs and symptoms.3 In the
early stage, respiratory symptoms and airflow limita-
tion form more or less independent aspects of
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chronic obstructive respiratory disease, and this
helps explain the underpresentation by patients and
underdiagnosis by (family) physicians of asthma and
COPD.4 With its resistance to interventions other
than smoking cessation,5 decline in FEV1 appears to
lose its central position in monitoring and managing
COPD.
COPD is the end stage of a development over a
long period of time, and this requires longitudinal
research. So far, population studies5,6 have mainly
focused on the rate of FEV1 decline in relation to
mortality or smoking behavior, whereas several ran-
domized controlled trials7–9 on inhaled corticosteroid
treatment also related health status outcome to the
progression of the disease. As yet, there are no
studies on early presentation of symptoms and their
prognostic value for the development of COPD in
the long term. In the mean time, Xie et al1 present a
longitudinal study demonstrating that the presence
of airflow limitation predicted health-related quality
of life 9 years later. Although the correlations found
were weak, they pointed in the same direction in all
domains. The findings of Xie et al1 are in agreement
with previous studies that showed that impaired
health and functional status are independently asso-
ciated with the severity of airflow limitation in
subjects with undiagnosed disease,8 as well as in
patients with established COPD.10 In our DIMCA
program,2 a representative sample of subjects with
formerly undiagnosed disease recruited in family
practice was screened for respiratory symptoms and
airflow limitation. Although the long-term follow-up
results from the DIMCA cohort have not been
published yet, our preliminary analyses show that
baseline lung function is indeed associated with
future respiratory health status as measured with the
Chronic Respiratory Questionnaire.11 After 5 years,
the group of subjects who were initially at risk for
chronic respiratory disease (who also had a lower
mean baseline postbronchodilator FEV1) showed a
mean Chronic Respiratory Questionnaire score that
was 0.3 point lower than in the subjects who initially
had good respiratory condition (5.95 0.89 points vs
6.24 0.56 points [ SD], p 0.007). The DIMCA
study also showed that impairment of quality of life
due to dyspnea and fatigue and variability in lung
function are better predictors of physician consulta-
tion than the mere presence of respiratory symptoms
or a (gradually) reduced lung function.12
It seems that the impact on quality of life comes
next to the impact on mortality (in the study of Xie et
al,1 an important reason for loss to follow-up among
those with initially low FEV1) and morbidity.13 In a
recent article, Thomas and Levy14 state that “as
COPD is an illness that has no cure, we must
continue to strive for early detection and active
management at all stages of the disease. The cycle of
inactivity, social isolation, depression and de-condi-
tioning so well described in COPD should be pre-
vented.” Xie et al1 conclude that the decrease of
quality of life is largely mediated through the devel-
opment of chronic respiratory symptoms. If symp-
toms do predict morbidity (and mortality) after all,
early detection of COPD can be easily implemented
in primary care practice by the use of office spirom-
etry. Further research should point out whether
early access to proactive care and thus to prophylac-
tic vaccination, pharmacologic and nonpharmaco-
logic treatment options, and early lifestyle interven-
tions (including smoking cessation, improved diet,
and increased exercise)4,9 prevents further deterio-
ration of quality of life.
It remains an interesting question how many of
the individuals in the study by Xie et al1 actually had
COPD. On the group level, impairment of baseline
pulmonary function had a negative impact on quality
of life in future years. However, the correlation of
FEV1 with quality of life was accompanied by a
broad spread: where some suffer, others with the
same degree of airflow limitation lead a relatively
unimpaired life. This reduces the possibility to pre-
dict the individual course and consequently early
detection of COPD.
And this brings us back at the heart of the matter.
FEV1 has been regarded a method for early detec-
tion of COPD, thus creating the opportunity of early
intervention. In fact, this was the underlying objec-
tive of the DIMCA program. With an observation
spanning 10 years, it has now become obvious to us
that a firm individual clinical diagnosis is necessary
for the interpretation of (group) correlations and
progression in early stage COPD. The way forward is
expected to come from adding analysis of individual
medical histories over time to the population studies,
in order to fine-tune this information and build
evidence-based case-finding: detection and monitor-
ing of patients with airflow limitation in order to
prevent further loss of quality of life.
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Implementation of Guidelines
on Hospital-Acquired
Pneumonia
Is There a Clinical Impact on
Outcome?
H ospital-acquired pneumonia (HAP) is a com-mon and serious clinical problem. In fact, it is
the second most frequent nosocomial infection and
the first in the ranking of mortality. The incidence of
HAP acquired outside the ICU has recently been
studied by Sopena et al1 in a multicenter study
reporting an incidence of 3 1.4 per 1,000 hospital
admissions and a crude mortality of 26% (14% of
attributable mortality). Ventilator-acquired nosoco-
mial pneumonia (VAP) is a form of HAP that
develops during mechanical ventilation. The overall
incidence ranges from 9 to 27% of intubated pa-
tients, accounting for a very high attributable mor-
tality (range, 33 to 50%). This variability in the
incidence and mortality of VAP reflects the different
populations studied, the different methods used for
diagnosis, as well as the different methods and
prevention programs implemented.2,3
There are some medical interventions that can
modify the outcome of HAP and VAP. The most
effective intervention is early and appropriate ad-
ministration of antibiotics.4,5 Initial appropriate anti-
biotic treatment is associated with lower mortality,
shorter length of stay, and lower number of compli-
cations.4 Multidrug-resistant (MDR) microorgan-
isms are responsible for a great proportion of inad-
equate initial treatments.4
The protocolization of the management of diseases
is a key issue in modern medicine and should be
carried out following evidence-based recommenda-
tions. In the last 10 years, several guidelines have
been published on respiratory infections such as
community-acquired pneumonia, COPD exacerba-
tions, and HAP. The utility of these guidelines has
been clearly demonstrated. For example, using a
“before-and-after” design, Dean and colleagues6
showed a decrease in mortality (from 13.4 to 11%)
after the implementation of the old American Tho-
racic Society (ATS) guidelines for CAP in a group of
hospitals.
In the study published in this issue of CHEST (see
page 2778), with the use of an observational cohort
study with preguideline and postguideline data col-
lection, Soo Hoo and colleagues7 studied the impact
of the implementation of the 1996 ATS HAP guide-
lines8 in 61 episodes of severe HAP. Interestingly,
implementation of the guidelines resulted in a higher
percentage of adequately treated patients (81% vs
46%) and a lower mortality at 14 days (8% vs 43%).
Appropriate imipenem use occurred in 74% of the
cases with no increase in the imipenem-resistant
microorganisms at the end of the study. This study
confirms that the implementation of evidence-based
protocols decreases the mortality in HAP. This type
of study is absolutely necessary to convince health-
care authorities and medical communities of the
importance of providing resources for the develop-
ment and implementation of guidelines. These com-
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